[HTML][HTML] Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm
J Unger - Journal of Osteopathic Medicine, 2011 - degruyter.com
Incretin-based therapies (subcutaneously administered glucagon-like peptide-1 [GLP-1]
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …
Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm
J Unger - The Journal of the American Osteopathic …, 2011 - pubmed.ncbi.nlm.nih.gov
Incretin-based therapies (subcutaneously administered glucagon-like peptide-1 [GLP-1]
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …
Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
J Unger - The Journal of the American Osteopathic Association, 2011 - europepmc.org
Incretin-based therapies (subcutaneously administered glucagon-like peptide-1 [GLP-1]
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …
agonists and oral dipeptidyl peptidase-4 inhibitors) represent a new mechanism of action …
Clinical Efficacy of GLP-1 Agonists and Their Place in the Diabetes Treatment Algorithm
degruyter.com
of type 2 diabetes. They may be used in a complementary fashion with more traditional
agents as part of combination treatment strategies. Both classes of incretins are excellent …
agents as part of combination treatment strategies. Both classes of incretins are excellent …